Published on Spencer Knight via LinkedIn Novartis is acquiring Regulus Therapeutics for up to $1.7 billion to expand its position in...

Published on Spencer Knight via LinkedIn The FDA has approved ZEVASKYN™, the first-ever autologous cell-based gene therapy for patients...

Published on Spencer Knight via LinkedIn Ferring Pharmaceuticals has emerged as a commercial frontrunner in gene therapy with the...

Published on Spencer Knight via LinkedIn Lisa Noble, 58, was given just two weeks to live after failing chemotherapy for B cell lymphoma....

Published on Spencer Knight via LinkedIn The NHS in England is fast-tracking a cancer vaccine trial for melanoma through its Cancer...

Published on Spencer Knight via LinkedIn Capstan Therapeutics has entered Phase 1 trials with CPTX2309, an in vivo CAR-T candidate that...

Published on Spencer Knight via LinkedIn BioSpace’s 2025 Life Sciences Salary Report highlights key compensation benchmarks in biotech....

Published on Spencer Knight via LinkedIn Hospital Clínic Barcelona-IDIBAPS has become a European leader in academic CAR-T, treating over...

Published on Spencer Knight via LinkedIn Neurona Therapeutics has secured $102 million to push forward its cell therapy NRTX-1001, which...

Published on Spencer Knight via LinkedIn Atsena Therapeutics has secured an oversubscribed $150 million Series C round, led by Bain...

Published on Spencer Knight via LinkedIn Multiple gene editing breakthroughs were announced in a single week, signaling strong momentum...

Published on Spencer Knight via LinkedIn Concerns about secondary cancers from CAR-T therapy may be overstated, according to new data. A...

Published on Spencer Knight via LinkedIn A 14-month-old boy named Tomas, born with a life-threatening liver disorder called OTC...

Published on Spencer Knight via LinkedIn AstraZeneca has acquired Belgian biotech EsoBiotec for $1 billion, including $425 million...

Published on Spencer Knight via LinkedIn Bristol Myers Squibb has acquired 2seventy bio in an all-cash deal worth $286 million, offering...

Published on Spencer Knight via LinkedIn CAR T-cell therapy has revolutionized oncology, but its next frontier is outside of cancer...

Published on Spencer Knight via LinkedIn There are more than 300 million people worldwide living with rare diseases, many of them with no...

Published on Spencer Knight via LinkedIn Regeneron has announced a major milestone in pediatric gene therapy using its DB-OTO treatment....

Published on Spencer Knight via LinkedIn A gene therapy trial at Moorfields Eye Hospital in London has given four children born with...

Published on Spencer Knight via LinkedIn Between 2004 - 2009, 19 children with neuroblastoma joined a CAR-T clinical trial at Baylor...